The Role of Osteocalcin in Placenta Function in Gestational Diabetes Mellitus

Liang Song  
Gynaecology and obstetric hospital of guangxi zhuang autonomous region

Yiming Huang  
Guangxi Medical University

Junqing Long  
Gyneacology and Obstetrics hospital of Guangxi zhuang autonomous region

Yuanfan Li  
Guangxi Medical University

Zongqin Pan  
Dalian Hospital of Obstetrics and Gynaecology

Fang Fang  
Gynaecology and obstetrics hospital of guangxi zhuang autonomous region

Yu Long  
Guangxi Medical University First Affiliated Hospital

Cheng Huang  
Guangxi Medical University

Nana Qi  
Guangxi Medical University

Yajie Guo  
Guangxi Medical University

Hongwei Xia  
Gyneacology and Obstetrics Hospital of Guangxi Zhuang Autonomous Region

yonghua jiang  
guangxi medical university  https://orcid.org/0000-0003-2927-4921

Keywords: Gestational diabetes mellitus, Osteocalcin, Placenta, Autocrine, Adiponectin.

DOI: https://doi.org/10.21203/rs.3.rs-379456/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Evidence for osteocalcin role in glucose and energy metabolism is increasing. However, little is known about osteocalcin function in gestational diabetes mellitus. The aim of this study is to examine the associations between osteocalcin and gestational diabetes mellitus.

Method: 36 patients with gestational diabetes mellitus and 40 normal glucose tolerance controls were recruited in the Maternal and Child Health Hospital Guangxi Zhuang Autonomous Region from May to August 2018. Total osteocalcin and biochemical indexes of maternal serum and umbilical vein serum were analyzed. Transcriptome of placenta were sequenced. Human trophoblast JAR cells were used for evaluated the affection of osteocalcin on trophoblast in vitro. There were no significant differences with maternal serum total osteocalcin levels between gestational diabetes mellitus and normal glucose tolerance groups. The gestational diabetes mellitus group has lower umbilical vein serum total osteocalcin (51.46 ng/mL ± 24.29 Vs 67.00 ng/mL ± 25.33, P = 0.008), lower adiponectin (1099.72 μg/L ± 102.65 Vs 1235.85 μg/L ± 94.63, P < 0.001), higher leptin (7.41 μg/L ± 0.28 Vs 6.02 μg/L ± 0.31, P < 0.001). A significant relationship existed between umbilical vein serum total osteocalcin levels and leptin (r = -0.456, P = 0.007). Osteocalcin promote JAR trophoblast cells proliferation and HCG synthesis. 36 correlated gene modules of placental transcriptome were identified through weighted gene co-expression network analysis, 2 of them were associated with osteocalcin.

Conclusion: lower osteocalcin in umbilical vein serum is associated with gestational diabetes mellitus, osteocalcin may regulate placenta function via adiponectin.

Background

Gestational diabetes mellitus (GDM) is defined as glucose intolerance that is first recognized during pregnancy. With the development of living level and the alteration of life style, the morbidity of gestational diabetes is about 30% worldwide [1]. Hyperglycemia leads to complications, such as macrosomia, gestational hypertension, and preterm delivery. Moreover, postpartum patients and GDM offspring often carry a lifelong increased risk of glucose intolerance and obesity [2, 3].

Osteocalcin (OCN) is an osteoblast-specific protein, Osteocalcin is the the most abundant non-collagenous proteins which constitute bone, un carboxylation OCN (ucOCN) released into the circulation, evident shows that ucOCN involved in the regulation of glucose and fat metabolism[4, 5]. OCN could decrease serum glucose levels either directly by increases pancreas beta cells insulin secretion or indirectly by promoting glucose consume by liver, adipocyte, muscle and so on[6, 7]. Both of these functions are mediated by the G-protein-coupled receptor GPR C6A [8–10], inducing the synthesis of adiponectin (ADP) in adipocytes, muscle and other tissues, then facilitating insulin sensitivity [4, 5].

It has been confirmed that OCN serum levels are lower in individuals with type 2 diabetes than in normal controls [9, 11, 12]. Although GDM resembles type 2 diabetes in some ways, there is no consensus regarding the OCN levels in GDM. The results of some epidemiological investigations reveals that
maternal OCN, especially the biological activity un carboxylation OCN (ucOCN) levels are significantly higher in GDM patients [13–15], others reveals that the OCN levels has no significant relation with GDM morbidity [11]. It is interesting that some research suggest that ADP levels are significantly lower in women with GDM and may help predict the risk of diabetes after GDM [16, 17]. Since ADP is the down effect protein of OCN, and during pregnancy, the placenta is one of the major source organs of ADP, so we hypothesized that it couldn’t exclude that OCN is involved in the occurrence of insulin resistance via the placenta. Therefore, the aim of this research is to examine the associations between OCN and GDM in GDM both in Maternal peripheral blood and umbilical cord blood.

Methods

Participants and clinical measurement

Subgroup 1 including 36 pregnant women with GDM and 40 matched normal glucose tolerance (NGT) pregnant women, subgroup 2 including 13 NGT pregnant women, all of them were recruited from May to August 2018, at The Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Department of Obstetrics. Inclusion and exclusion criteria are shown in Tab. S1. Written informed consent was obtained from all participants, and the study was approved by The Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region ethics committee.

Pre-pregnancy body mass index (BMI) was calculated according to weight before pregnancy as weight (in kilograms)/height (in square meters). Birthweight, neonatal gender, delivery mode, placental size and weight, neonatal peripheral blood glucose levels were obtained from patient medical records.

Biochemical analysis

Maternal blood samples were taken from a cannulated vein before delivery, gestational diabetes mellitus umbilical vein (Uv) blood and umbilical artery (Ua) blood were taken from the umbilical cord venous and arterial storing in the vacuum blood collection tube during the third stage of labor. All blood samples were centrifuged (3000 rpm at room temperature for 5 minutes), and serum were collected in the 1.5 mL Eppendorf tubes. Placental tissue from the central cotyledon about 1 cm³ was obtained immediately after delivery. Serum aliquots and placental tissues were immediately stored at -80°C until analysis.

Measurement of serum indicators

The levels of total OCN (tOCN), 1,25-(OH)2-VitD₃ (25(OH)D₃), parathormone, insulin glucose, triglycerides (TG), total cholesterol (TC), high density lipoprotein total cholesterol (HDL-C), alkaline phosphatase (ALP), human chorionic gonadotropin (HCG), and estradiol (E₂) were analyzed by electrochemiluminescence immunoassay on COBAS 6000 system E601 (Elecsysmodule) immunoassay analyzers (Roche Diagnostics, GmbH, Mannheim, Germany). Leptin (LEP), ADP, and tartrate-resistant acid phosphatase 5b (TRACP-5b) were measured by ELISA kits according to the manufacturers’ instructions (Shanghai Guangrui Biotechnology Co., Ltd).
serum cytokines analysis

8 serum cytokines, IL-2, IL-4, IL-6, IL-8, IL-10, IL-17A, IFN-γ, TNF-α, were analyzed on Bio-Plex liquid chip platform. Briefly, the biotinylated detection antibody was added into a 96-well plate, serum sample were mixed with the antigens coupled microspheres and added into each hole, then adding streptavidin phycoerythrin, detecting the fluorescence signal by a Bio-Plex liquid chip system, and judging the positive property/negative property of the sample according to the strength of the fluorescence signal.

RNA extraction and qRT-PCR

RNA extraction and purification were conducted using the E.Z.N.A.™ Total RNA Kit I (Omega). cDNA synthesis was performed using the PrimeScript™ RT Reagent Kit (Takara). SYBR Premix Ex Taq™ (Tli RNaseH Plus) was used with the following PCR parameters, 1 cycle of 30 s at 95 ℃ and then 40 cycles of 95 ℃ for 5 s and 1 cycle of 30s at 60 ℃. qRT-PCR was conducted using a LightCycler 96 (Roche). The primer sequences are presented in Tab. S2. The housekeeping gene β-actin was used as control. The relative levels of the mRNA of the genes of interest were normalized to the β-actin mRNA.

Immunohistochemistry

Placenta tissues were washed 3 times in PBS for 30 seconds and fixed in 4% formaldehyde for 24 hours. The placental tissues were then embedded in paraffin and sectioned at a thickness of 5 μm. The tissue sections were deparaffinized, subjected to high-temperature antigen exposure, rehydrated in 3% H2O2, and blocked with 10% normal goat serum for 30 minutes. The sections were then incubated with antibodies to OCN (1:1000) (Santa cruz) or GPRC6A (1:1000) (Invitrogen). The secondary antibodies are provided with the DAB Substrate Kit for Peroxidase (Vector Laboratories). Olympus DP11 camera and Olympus Camedia software were used to produce the images.

In vitro experiments

Cell culture: JAR trophoblast cells were giving by professor Longyu, JAR cells were maintained without antibiotics and RPMI-1640 medium (Gibco) containing 10% fetal bovine serum (FBS) (Gibco) at 37 ℃ under 5% CO2. Osteogenic induction medium: α-MEM (Gibco) containing 10% FBS (fetal bovine serum), 100 nM dexamethasone (Sigma), 5 mM β-phosphoglyceride (Sigma) and 5 μg/mL vitamin C (Sigma).

Alizarin red stain: Alizarin red stain positive indicate calcium. JAR cells were maintained in 6 well plate until 90% confluency. Osteogenic induction medium was added confluency to 6 well plate to maintain 7 days, and then JAR cells were fixed by 4% paraformaldehyde for 10 minutes. Adding alizarin red for 5 minutes. At each of steps, JAR cells were washed for 3 times by PBS.

Scanning electron microscope: JAR cells were maintained in 24 well plate until 80%. Osteogenic induction medium was added to 24 well plate to maintain 7 days. 3% glutaraldehyde was used to fixed JAR cells. The calcium nodules were observed by scanning electron microscope (Czech, TESCAN, VEGA 3 LMU).
Cell proliferation assay: Using the Cell Counting Kit-8 (CCK-8, Solarbio®) according to the manufacturer's instructions. This experiment was performed in triplicate.

shRNA knockdown: Human GPRC6A shRNA lentivirus plasmid pLV[shRNA]-EGFP: T2A: Puro-U6 > hGPRC6A purchases from Victor builder company (Saiye). Lipofectamine 2000 (Invitrogen) was used to package virus in 293T cells; a 5:3:2 ratio of target plasmid: psPAX2: PMD2G was used. Virus supernatant (100 μL) was added to JAR cells in 24-well plates for 24 hours. Green fluorescence could be observed after 72 h.

RNA sequencing and bioinformatics analysis

RNA sequencing: Total RNA was extracted from placental tissues using the E.Z.N.A.™ Total RNA Kit I (Omega). mRNA sequencing was performed on an Illumina HiSeq 4000 RNA-sequencing platform, and the results were uploaded to BaseSpace of the Illumina cloud server. The RNA-Seq Alignment and Cufflinks Assembly procedures were used in the sequencing analysis.

WGCNA: Co-expression networks were constructed using the WGCNA (v1.47) package in R. Without filtering the genes, gene expression values were imported into WGCNA and used to construct co-expression modules using the automatic network construction function block wise modules with default settings except that the power was set to 2. TOM Type was unsigned, and the minimum module size was 250. The genes were clustered into 36 correlated modules. Module eigengenes were used to calculate the correlation coefficients for samples or sample traits.

Gene ontology (GO) analysis: significantly enriched GO terms pathways were defined by the hypergeometric test using a threshold false discovery rate (FDR) ≤ 0.05.

RNA-Seq data to this article can be found online at https://www.ncbi.nlm.nih.gov/sra/, SRR10812151-SRR10812189.

Statistical analyses

Statistical analyses were undertaken using SPSS 25(IBM, Chicago, IL, USA). The results are reported as the mean ± S.D. unless otherwise noted. Clinical characteristics that followed a normal distribution were compared between the two groups using Student's t-test. Categorical variables were analyzed using the \( \chi^2 \) test. Spearman's correlation was used to examine associations between serum OCN and metabolic indices. Statistical analysis and graph plotting were performed using Prism 7 software and Adobe Illustrator. \( P < 0.05 \) was considered significant.

Results

No significant differences with maternal serum tOCN levels between GDM and NGT groups in third trimester
36 GMD patients and 40 NGT control participants were recruited. Compared with the NGT controls, GDM patients had higher maternal age, pre-pregnancy BMI, systolic blood pressure, diastolic blood pressure, and C-reactive protein. Overall weight gain was significantly lower in GDM patients than in the controls. However, there were no significant differences with maternal serum tOCN levels between GDM and NGT groups (14.46 ng/mL ± 10.19 Vs 16.01 ng/mL ± 8.54, $P = 0.472$) (Tab. 1).

**The Uv serum tOCN levels is lower in GDM patient**

Birth length and head circumference were significantly higher in the GDM group than in the NGT control group, but there was no difference in birth weight (Tab. S3). Interestingly, The Uv serum tOCN levels is significantly lower in GDM patient than in the NGT controls (51.46 ± 24.29 ng/mL Vs 67.00 ng/mL ± 25.33, $P = 0.008$). Meanwhile ADP is lower in the GDM group (1099.72 μg/L ± 102.65 Vs 1235.85 μg/L ± 94.63, $P < 0.001$), while LEP is higher in GDM group (7.41 μg/L ± 0.28 Vs 6.02 μg/L ± 0.31, $P < 0.001$). blood glucose24-28 weeks OGTT, fasting, 1, 2-hour glucose were higher in the GDM group, all $P<0.001$. the Fasting Glucose before delivery show rising trend in the GDM group, but has no significant different, $P=0.074$

Spearman's correlation analysis is shown that Uv serum tOCN levels were negatively correlated with LEP and neonatal peripheral blood glucose ($R = -0.456$, $P = 0.007$ and $R = -0.278$, $P = 0.026$, respectively) and positively correlated with TNF-α ($R = 0.395$, $P = 0.016$). It is not significantly correlated with birth weight, birth length and chest circumference, or bone metabolism indexes 25(OH)D$_3$ and TRACP-5b (Tab. 2).

**OCN exerts autocrine loop in trophoblast**

Since there is no obvious correlation between Uv serum tOCN levels and fetal bone mass, we suspected that some of the OCN present in Uv blood may be produced by trophoblast cells. To test this prediction, firstly, the concentrations of total OCN in maternal peripheral blood and in Ua and Uv were measured in 13 healthy pregnant women, the serum sample was collected during pre-delivery or third stage of labor. The tOCN concentration in Uv serum was significantly higher than that in maternal serum and Ua serum (Fig. 1 a). Secondly, OCN and its receptor GPRC6A expression were verified by placenta immunohistochemistry staining, which were positive expression in syncytiotrophoblasts (N=3;Fig. 1b). Thirdly, the ability of trophoblasts to synthesis OCN was further investigated by JAR trophoblast cells human. 7 days after osteoblast induction, qRT-PCR analysis revealed that the bone formation-related genes *OCN, Dmp1, CollA1* were highly expressed in osteogenesis induces differentiated JAR cells (Fig. 1c). JAR cells showed the presence of mineralized nodules within the cells, indicated by Alizarin Red stained or transmission electron microscopic images staining (Fig. 1d).

**OCN affected JAR trophoblast cells function**

To determine the effects of OCN on JAR trophoblasts cells, 100 ng/ml OCN was added to the culture medium. OCN markedly promoted JAR cells proliferation and HCG synthesis. qRT-PCR analysis is shown that ADP expression is increased while LEP expression is decreased, meanwhile enzymes associated with
steroid hormone metabolism such as CYP-11A1, CYP-19A1, CYP-27B1, HSD-17B1, and inflammatory factors IL-6, TNF-α were significantly increased than without AND (Fig. 1e-g).

GPRC6A is the receptor of OCN, and GPRC6A was knockdown in JAR trophoblast cells which was confirmed by qRT-PCR (Fig. S1). As expected, shRNAs targeting GPRC6A efficiently attenuated JAR trophoblast cells proliferation and HCG synthesis. LEP, ADP, enzymes associated with steroid hormone metabolism and inflammatory factors were also affected by GPRC6A shRNA (Fig. 1h-j). *P<0.001*

**Placenta mRNA sequence analysis found 6 modules correlated with ADP and LEP**

mRNA sequence analysis was performed on 39 (GDM=18, NGT=21) placental samples. A total of 18329 genes were detected and selected for subsequent analysis. Co-expression modules were constructed using the WGCNA (v1.47) package in R. Scale-free networks were constructed in which the power value was equal to 2 (Fig. S2a). The grey module, which consisted of genes not belonging to any other module, was excluded, then 36 distinct gene co-expression modules were separated (Fig. S2b).

There are 2 modules show the highest correlations with osteocalcin (Fig. 2). The darkturquoise (n = 355 genes), darkmagenta (n = 269 genes), showed positive correlations with osteocalcin (Fig. 2).

The enriched GO biological processes, molecular function and cellular component were used to show the gene function of two correlations darkmagenta and darkturquoise module. The genes in the darkturquoise module appear to be enriched in glucagon receptor activity, brown fat cell differentiation. darkmagenta module corresponded to muscle system process, cAMP-dependent protein kinase regulator activity (Fig. S3).

Hub genes for the modules of interest were chosen according to the criteria MM (Module Membership) > 0.8, GS(Gene Significance) > 0.4 and significantly (P < 0.05) correlated with osteocalcin. (Fig. S4, Tab. S4).

**Discussion**

We found no differences in maternal serum OCN in GDM and NGT groups, in fact, the levels of OCN Uv serum were lower in the GDM group than those in NGT group, these result was consisted with previous research, which demonstrated that in the third trimester or predelivery OCN has no significant difference between GDM and control group [11, 13]. What we go further than these reports are that we analyze the relationship between OCN and biochemical indexes in Uv serum. Our result suggest that the OCN levels in Uv serum were lower in GDM patient. Uv OCN was negatively correlated with Uv LEP and fetal blood glucose. Based on these founding we guess that maybe the placenta could synthesis OCN by itself, further research reveal that Uv serum concentrations of OCN are higher than that in Ua serum and maternal peripheral blood plasma concentrations, suggesting that the steroidal environment of the placenta differs significantly from that in maternal peripheral blood.
By placenta immunohistochemical staining and in vitro JAR trophoblast cells experiment, we identified a potential OCN autocrine feed-forward loop in the placenta. OCN is the most abundant non-collagenous protein found in the skeleton and was previously thought to be expressed only in mature osteoblasts. However, there is increasing evidence regarding the ectopic production OCN by other organs. This is not the first report about that OCN expression was found in placenta tissue. Telejko had reported that OCN mRNA were detected in placenta tissue [18]. Moreover, it has been reported that OCN is expressed in adipose tissue [18–20], tendon sheath tissues [21], endothelial progenitor cells [22], and prostate cancer [23] and so on. The function of ectopic production OCN in placenta is worth further investigation.

It is believed that OCN facilitates insulin sensitivity by inducing the expression of ADP through the GPRC6A receptor [4, 24]. ADP is a well-known gene involved in glucose metabolism regulation, which promotes sugar uptake and reduces gluconeogenesis in liver and muscle, resulting in reduced insulin resistance and promoting insulin sensitivity [25, 26]. The level of insulin resistance during pregnancy is closely associated with proteins secreted by the placenta, such as ADP, inflammatory cytokines and so on [27]. A consensus has been reached that lower ADP levels are significantly correlated with insulin secretion and IR indices in GDM [28, 29]. However, it is unclear that OCN plays a role in glucose homeostasis through placenta or mediated through ADP during pregnancy.

In this research we reported that OCN synthesis by trophoblast, in vitro JAR trophoblast cells experiment proved that OCN favorable ADP, sex hormone, adipocyte cytokine production. mRNA sequencing of placenta and subsequent WGCNA analysis was performed for further investigate the OCN function in the placenta. It is interesting that 2 of 36 module show correlations with osteocalcin, including darkmagenta and darkturquoise. Hub genes were identified in these two modules. Some of these genes have been reported to be associated with diabetes or lipid metabolism, such as MAGI1 [30], ACTC1 [31], ACTA1 [32]. Overall, the result suggested that repress OCN in placenta regulated trophoblast function through ADP. Although some of these genes have been reported to be associated with glucolipid metabolism, their importance in placenta metabolic programming and the relationship with OCN and ADP require further investigation.

The relationship between Uv OCN and neonatal growth index, 25(OH)D₃ were not found out. Uv OCN is negative associated with neonatal peripheral blood glucose. Importantly, LEP is negative correlated with Uv OCN. LEP is mainly secreted by placenta regulating the insulin sensitivity, insulin secretion as well as glucose and lipid metabolism [33]. The level of LEP has an important role in bone metabolism. Previous study report that LEP deficient ob / ob and LEP resistant db / db can increase osteocalcin levels [34]. However, other research shows that LEP increase osteoblast-specific osteocalcin [35]. One explanation may be the different sources of LEP. Uv LEP may mainly secreted by the placenta to satisfy materal and fetal growth during pregnancy.

In this research, the Uv OCN is positively correlated with TNF-α, and GPRC6A knockdown JAR cells model was stimulated by OCN increased secreting IL-6 and TNF-α. The role of OCN in inflammation in human beings is still unconclusive. The previous study suggest that OCN improves whole - body insulin
resistance by decreasing inflammation, and increasing insulin signaling and the expression of Slc2a4/GLUT4 [36]. Moreover, OCN could be a therapeutic target for protecting against chronic inflammation in T2D [37].

**Limitations Of The Study**

The limitations of this study are as follows. 1) This is a study of a small sample of women in southern China. Although is neonate birth weight and Maternal peripheral blood glucose higher in GDM group, but there was no statistic difference, which may be the sample size is too small, still need a large number of high quality. 2) OCN has two molecular forms, carboxylated or ucOCN, it is ucOCN appears linked endocrine function. Although tOCN may reflect indirectly ucOCN levels, it is still very regret that only tOCN, not specifically ucOCN was measured in this research. 3) This is a cross-sectional study, the findings reported here do not necessarily reflect causal associations. 4) OCN were strongly expressed in syncytiotrophoblasts by immunohistochemistry, however, for verification the trophoblast OCN synthesis ability, we use Jar cells, which are cytotrophoblasts.

**Conclusion**

In the third trimester, lower osteocalcin concentration of umbilical venous serum is associated with gestational diabetes mellitus. Osteocalcin exerts autocrine loop in trophoblast may regulate placenta function via adiponectin.

**Abbreviations**

GDM, gestational diabetes mellitus; NGT, normal glucose tolerance; BMI, Body Mass Index; SBP, systolic blood pressure; DBP, diastolic blood pressure; OGTT, oral glucose tolerance test; OCN, osteocalcin; 25(OH)D3, 1,25-(OH)2-VitD3; CRP, C-reactive protein; ALP, alkaline phosphatase; HOMA-IR, homeostasis model assessment of insulin resistance; HDL-C, high density lipoprotein total cholesterol; TC, total cholesterol; TG, triglyceride; HCG, human chorionic gonadotropin; E2, estradiol; TRACP-5b, tartrate-resistant acid phosphatase 5b; LEP, leptin; ADP, adiponectin; IL, interleukin; IFN γ, interferon γ; TNF-α, tumor necrosis factor α. Uv, umbilical vein;

**Declarations**

**Availability of data and materials**

RNA-Seq data to this article can be found online at https://www.ncbi.nlm.nih.gov/sra/, SRR10812151-SRR10812189.

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Acknowledgements

We thank the women who participated in the study. The authors gratefully acknowledge the research assistants for their commitment during data collection.

Funding

This work was supported by the National Natural Science Foundation of China to Y.H. and Y.L. (81501284, 81960282), the Natural Science Foundation of Guangxi Zhuang Autonomous Region to Y.L. (2017GXNSFBA198084, 2020GXNSFDA297024).

Authors’ contributions

Y.J., and H.X. conceived and designed the experiments. L.S., C.H., Z.P., F.F., J. L., and Y.L. performed the epidemiologic study. H.Y. performed the cell biology experiments. H.Y., N.Q., and Y.G. performed the pathology and immunohistochemistry experiments. Y.H. performed the bioinformatic analysis experiments. Y.J. and Y.H. wrote the manuscript.

Ethics declaration

The study was approved by The Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region ethics committee.

Consent for publication

This manuscript contains no individual person’s data in any form and consent for publication is not applicable for this section.

Competing interests

All authors declared no competing interests.

References

1. Mahany EB, Han X, Borges BC, da Silveira Cruz-Machado S, Allen SJ, Garcia-Galiano D, Hoenerhoff MJ, Bellefontaine NH, Elias CF. Obesity and High-Fat Diet Induce Distinct Changes in Placental Gene Expression and Pregnancy Outcome. Endocrinology. 2018;159(4):1718–33.
2. Jovanovic L, Liang Y, Weng W, Hamilton M, Chen L, Wintfeld N. Trends in the incidence of diabetes, its clinical sequelae, and associated costs in pregnancy. Diabetes Metab Res Rev. 2015;31(7):707–16.
3. Zhang C, Rawal S, Chong YS. Risk factors for gestational diabetes: is prevention possible? Diabetologia. 2016;59(7):1385–90.
4. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130(3):456–69.

5. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A. 2008;105(13):5266–70.

6. Liu DM, Mosialou I, Liu JM. Bone: Another potential target to treat, prevent and predict diabetes. Diabetes Obes Metab. 2018;20(8):1817–28.

7. Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, Yano S, Sugimoto T. Adiponectin is associated with changes in bone markers during glycemic control in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94(8):3031–7.

8. Otani T, Mizokami A, Hayashi Y, Gao J, Mori Y, Nakamura S, Takeuchi H, Hirata M. Signaling pathway for adiponectin expression in adipocytes by osteocalcin. Cell Signal. 2015;27(3):532–44.

9. Mera P, Ferron M, Mosialou I. Regulation of Energy Metabolism by Bone-Derived Hormones. Cold Spring Harb Perspect Med 2018, 8(6).

10. Wei J, Hanna T, Suda N, Karsenty G, Ducy P. Osteocalcin promotes beta-cell proliferation during development and adulthood through Gprc6a. Diabetes. 2014;63(3):1021–31.

11. Saucedo R, Rico G, Vega G, Basurto L, Cordova L, Galvan R, Hernandez M, Puello E, Zarate A. Osteocalcin, under-carboxylated osteocalcin and osteopontin are not associated with gestational diabetes mellitus but are inversely associated with leptin in non-diabetic women. J Endocrinol Invest. 2015;38(5):519–26.

12. Al Rifai O, Chow J, Lacombe J, Julien C, Faubert D, Susan-Resiga D, Essalmani R, Creemers JW, Seidah NG, Ferron M. Proprotein convertase furin regulates osteocalcin and bone endocrine function. J Clin Invest. 2017;127(11):4104–17.

13. Tabatabaei N, Giguere Y, Forest JC, Rodd CJ, Kremer R, Weiler HA. Osteocalcin is higher across pregnancy in Caucasian women with gestational diabetes mellitus. Can J Diabetes. 2014;38(5):307–13.

14. Winhofer Y, Handisurya A, Tura A, Bittighofer C, Klein K, Schneider B, Biegelmayer C, Wagner OF, Pacini G, Luger A, et al. Osteocalcin is related to enhanced insulin secretion in gestational diabetes mellitus. Diabetes Care. 2010;33(1):139–43.

15. Martinez-Portilla RJ, Villafan-Bernal JR, Lip-Sosa DL, Meler E, Clotet J, Serna-Vela FJ, Velazquez-Garcia S, Serrano-Diaz LC, Figueras F. Osteocalcin Serum Levels in Gestational Diabetes Mellitus and Their Intrinsic and Extrinsic Determinants: Systematic Review and Meta-Analysis. J Diabetes Res. 2018;2018:4986735.

16. Mohammadi T, Paknahad Z. Adiponectin Concentration in Gestational Diabetic Women: a Case-Control Study. Clin Nutr Res. 2017;6(4):267–76.

17. Retnakaran R, Qi Y, Connelly PW, Sermer M, Hanley AJ, Zinman B. Low adiponectin concentration during pregnancy predicts postpartum insulin resistance, beta cell dysfunction and fasting glycaemia. Diabetologia. 2010;53(2):268–76.
18. Telejko B, Kalejta K, Kuzmicki M, Wawrusiewicz-Kurylonek N, Lipinska D, Pliszka J, Wilk J, Zielinska A, Sobota A, Szamatowicz J, et al. The association of bone turnover markers with pro- and anti-inflammatory adipokines in patients with gestational diabetes. Ann Agric Environ Med. 2015;22(2):307–12.

19. Aguiari P, Leo S, Zavan B, Vindigni V, Rimessi A, Bianchi K, Franzin C, Cortivo R, Rossato M, Vettor R, et al. High glucose induces adipogenic differentiation of muscle-derived stem cells. Proc Natl Acad Sci U S A. 2008;105(4):1226–31.

20. Foresta C, Strapazzon G, De Toni L, Gianesello L, Calcagno A, Pilon C, Plebani M, Vettor R. Evidence for osteocalcin production by adipose tissue and its role in human metabolism. J Clin Endocrinol Metab. 2010;95(7):3502–6.

21. Wang Y, Zhang X, Huang H, Xia Y, Yao Y, Mak AF, Yung PS, Chan KM, Wang L, Zhang C, et al: Osteocalcin expressing cells from tendon sheaths in mice contribute to tendon repair by activating Hedgehog signaling. *Elife* 2017, 6.

22. Gossl M, Modder UI, Atkinson EJ, Lerman A, Khosla S. Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol. 2008;52(16):1314–25.

23. Yang Y, Bai Y, He Y, Zhao Y, Chen J, Ma L, Pan Y, Hinten M, Zhang J, Karnes RJ, et al. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2018;24(4):834–46.

24. Oury F, Ferron M, Huizhen W, Confavreux C, Xu L, Lacombe J, Srinivas P, Chamouni A, Lugani F, Lejeune H, et al. Osteocalcin regulates murine and human fertility through a pancreas-bone-testis axis. J Clin Invest. 2013;123(6):2421–33.

25. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288–95.

26. Buday B, Pach FP, Literati-Nagy B, Vitai M, Vecsei Z, Koranyi L. Serum osteocalcin is associated with improved metabolic state via adiponectin in females versus testosterone in males. Gender specific nature of the bone-energy homeostasis axis. Bone. 2013;57(1):98–104.

27. Zatalia SR, Sanusi H. The role of antioxidants in the pathophysiology, complications, and management of diabetes mellitus. Acta Med Indones. 2013;45(2):141–7.

28. Gao XL, Yang HX, Zhao Y. Variations of tumor necrosis factor-alpha, leptin and adiponectin in mid-trimester of gestational diabetes mellitus. Chin Med J (Engl). 2008;121(8):701–5.

29. Soheilykhah S, Mohammadi M, Mojibian M, Rahimi-Saghand S, Rashidi M, Hadinedoushan H, Afkhami-Ardekani M. Maternal serum adiponectin concentration in gestational diabetes. Gynecol Endocrinol. 2009;25(9):593–6.

30. Abe JI, Ko KA, Kotla S, Wang Y, Paez-Mayorga J, Shin IJ, Imanishi M, Vu HT, Tao Y, Leiva-Juarez MM, et al: MAGI1 as a link between endothelial activation and ER stress drives atherosclerosis. *JCI insight* 2019, 4(7).
31. da Rocha RG, Santos EMS, Santos EM, Gomes ESB, Ramos GV, Aguiar KM, Gonçalves BR, Santos SHS, De Paula AMB, Guimarães ALS, et al. Leptin impairs the therapeutic effect of ionizing radiation in oral squamous cell carcinoma cells. Journal of oral pathology medicine: official publication of the International Association of Oral Pathologists the American Academy of Oral Pathology. 2019;48(1):17–23.

32. Gineste C, Duhamel G, Le Fur Y, Vilmen C, Cozzone PJ, Nowak KJ, Bendahan D, Gondin J. Multimodal MRI and (31)P-MRS investigations of the ACTA1(Asp286Gly) mouse model of nemaline myopathy provide evidence of impaired in vivo muscle function, altered muscle structure and disturbed energy metabolism. PloS one. 2013;8(8):e72294.

33. Masuzaki H, Ogawa Y, Sagawa N, Hosoda K, Matsumoto T, Mise H, Nishimura H, Yoshimasa Y, Tanaka I, Mori T, et al. Nonadipose tissue production of leptin: Leptin as a novel placenta-derived hormone in humans. Nat Med. 1997;3(9):1029–33.

34. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100(2):197–207.

35. Kalra SP, Dube MG, Iwaniec UT. Leptin increases osteoblast-specific osteocalcin release through a hypothalamic relay. Peptides. 2009;30(5):967–73.

36. Guedes JAC, Esteves JV, Morais MR, Zorn TM, Furuya DT. Osteocalcin improves insulin resistance and inflammation in obese mice: Participation of white adipose tissue and bone. Bone. 2018;115:68–82.

37. Kanazawa I, Tanaka S, Sugimoto T: The Association Between Osteocalcin and Chronic Inflammation in Patients with Type 2 Diabetes Mellitus. Calcified tissue international 2018, 103(6):599–605.

Tables

Table 1. Clinical and biochemical characteristics of the GDM and NGT groups.
|                                      | GDM                  | NGT                  | p      |
|--------------------------------------|----------------------|----------------------|--------|
|                                      | N (%) or mean ± SD   | N (%) or mean ± SD   |        |
| N                                    | 36                   | 40                   |        |
| Maternal age (years)                 | 32.86±4.20           | 30.33±3.09           | 0.004  |
| Ethnicity                            |                      |                      | 0.222  |
| Han                                  | 17(47.2)             | 26(65.0)             |        |
| Zhuang                               | 18(50.0)             | 13(32.5)             |        |
| Others                               | 1(2.8)               | 1(2.5)               |        |
| Pre-pregnancy BMI (kg/m²)            | 24.39±3.39           | 21.08±3.17           | 0.001  |
| Overall weight gain (kg)             | 9.91±5.08            | 13.77±2.69           | 0.001  |
| Blood pressure (mmHg)                |                      |                      |        |
| SBP                                  | 117.94±11.18         | 113.05±8.52          | 0.044  |
| DBP                                  | 76.19±8.51           | 70.58±10.01          | 0.011  |
| Parity                               |                      |                      | 0.365  |
| Primiparous                          | 31(86.1)             | 37(92.5)             |        |
| Multiparous                          | 5(13.9)              | 3(7.5)               |        |
| Mode of delivery                     |                      |                      | 0.812  |
| Vaginal                              | 28(77.8)             | 32(80.0)             |        |
| Caesarean section                    | 8(22.2)              | 8(20.0)              |        |
| 24-28 weeks OGTT (mg/dL)             |                      |                      |        |
| Fasting glucose                      | 5.05±1.11            | 4.3±0.44             | 0.001  |
| 1-hour glucose                       | 10.81±1.30           | 6.99±1.49            | 0.001  |
| 2-hour glucose                       | 9.03±1.78            | 6.28±1.34            | 0.001  |
| Maternal serum before delivery:      |                      |                      |        |
| OCN (ng/mL)                          | 14.46±10.19          | 16.01±8.54           | 0.472  |
| 25(OH)D₃ (ng/mL)                     | 22.74±7.75           | 19.54±6.80           | 0.059  |
| CRP (mg/dL)                          | 71.09±42.75          | 44.44±31.92          | 0.015  |
| ALP (U/L)                            | 162.97±50.11         | 158.38±52.26         | 0.701  |
| Fasting Insulin (μIU/mL)             | 42.67±79.74          | 47.03±36.88          | 0.742  |
| Test                        | Umbilical Vein Serum | Fasting Glucose (mg/dL) | HOMA-IR |
|-----------------------------|----------------------|-------------------------|---------|
| Fasting Glucose (mg/dL)     | 5.31±2.64            | 6.35±2.40               | 0.074   |
| HOMA-IR                    | 16.01±39.70          | 15.68±16.53             | 0.962   |
| Umbilical vein serum:       |                      |                         |         |
| Parathormone (pg/mL)        | 6.15±6.74            | 5.99±2.61               | 0.891   |
| **Insulin (μU/mL)**         | **19.79±32.39**      | **8.14±5.92**           | **0.028** |
| Glucose (mmol/L)            | 4.60±2.56            | 6.35±2.40               | 0.574   |
| OCN (ng/mL)                 | 51.46±24.29          | 67.00±25.33             | 0.008   |
| 25(OH)D3 (ng/mL)            | 28.79±8.86           | 25.62±10.11             | 0.152   |
| **ALP (U/L)**               | **156.12±38.89**     | **179.66±52.70**        | **0.031** |
| HDL-C (mmol/L)              | 0.97±0.24            | 1.05±0.28               | 0.200   |
| TC (mmol/L)                 | 1.83±0.61            | 1.86±0.49               | 0.836   |
| TG (mmol/L)                 | 0.33±0.14            | 0.25±0.14               | 0.095   |
| HCG (mIU/mL)                | 80.59±58.75          | 62.21±55.16             | 0.167   |
| E2 (pg/mL)                  | 12863.80±13743.04    | 10825.14±10183.10       | 0.462   |
| TRACP-5b (ng/L)             | 210.85±15.71         | 240.91±13.30            | 0.001   |
| LEP (μg/L)                  | 7.41±0.28            | 6.02±0.31               | 0.001   |
| ADP (μg/L)                  | 1099.72±102.65       | 1235.85±94.63           | 0.001   |
| IL-2 (pg/mL)                | 0.56±0.52            | 0.72±0.78               | 0.601   |
| IL-4 (pg/mL)                | 4.20±3.19            | 4.51±3.17               | 0.601   |
| IL-6 (pg/mL)                | 7.22±13.34           | 7.04±16.88              | 0.960   |
| IL-8 (pg/mL)                | 10.36±21.78          | 8.45±12.09              | 0.634   |
| IL-10 (pg/mL)               | 6.78±13.41           | 22.82±66.13             | 0.157   |
| IL-17 (pg/mL)               | 1.16±0.71            | 1.16±0.48               | 0.997   |
| IFYG (pg/mL)                | 1.26±1.20            | 1.55±1.08               | 0.408   |
| TNF-α (pg/mL)               | 8.19±2.07            | 9.29±2.91               | 0.065   |

GDM, gestational diabetes mellitus; NGT, normal glucose tolerance; BMI, Body Mass Index; SBP, systolic blood pressure; DBP, diastolic blood pressure; OGTT, oral glucose tolerance test; OCN, osteocalcin; 25(OH)D3, 1,25-(OH)2-VitD3; CRP, C-reactive protein; ALP, alkaline phosphatase; HOMA-IR, homeostasis model assessment of insulin resistance; HDL-C, high density lipoprotein total cholesterol; TC, total cholesterol; TG, triglyceride; HCG, human chorionic gonadotropin; E2, estradiol; TRACP-5b, tartrate-
resistant acid phosphatase 5b; LEP, leptin; ADP, adiponectin; IL, interleukin; IFN-γ, interferon γ; TNF-α, tumor necrosis factor α.

Table 2. Correlations between osteocalcin and parameters of biochemical index.
|                           | Uv OCN (ng/mL) | R  | P     |
|---------------------------|---------------|----|-------|
| **Neonatal**              |               |    |       |
| Birth weight (kg)         | -0.108        | 0.382 |
| Birth length (cm)         | -0.159        | 0.195 |
| Chest circumference (cm)  | -0.072        | 0.557 |
| Head circumference (cm)   | -0.069        | 0.574 |
| **Umbilical vein serum**  |               |    |       |
| Insulin (μU/mL)           | -0.164        | 0.180 |
| Glucose (mmol/L)          | -0.132        | 0.288 |
| 25(OH)D$_3$ (ng/mL)       | -0.030        | 0.809 |
| **ALP (U/L)**             | **-0.275**    | **0.023** |
| HDL-C (mmol/L)            | -0.109        | 0.377 |
| TC (mmol/L)               | -0.126        | 0.304 |
| **TG (mmol/L)**           | **-0.295**    | **0.014** |
| HCG (mIU/mL)              | -0.127        | 0.307 |
| E$_2$ (pg/mL)             | -0.166        | 0.177 |
| TRACP-5b (ng/L)           | 0.168         | 0.343 |
| **LEP (μg/L)**            | **-0.456**    | **0.007** |
| ADP(μg/L)                 | 0.194         | 0.272 |
| **Neonatal peripheral blood glucose (mg/dL)** | **-0.278** | **0.026** |
| **Inflammatory cytokines**|               |    |       |
| IL-2 (pg/mL)              | -0.186        | 0.270 |
| IL-4 (pg/mL)              | -0.161        | 0.340 |
| IL-6 (pg/mL)              | -0.260        |       |
| IL-8 (pg/mL)              | -0.193        | 0.253 |
| IL-10 (pg/mL)             | -0.173        | 0.307 |
| IL-17A (pg/mL)            | -0.079        | 0.642 |
| IFN-γ (pg/mL)             | -0.233        | 0.165 |
TNF-α (pg/mL) | 0.395 | 0.016

Uv, umbilical vein; OCN, osteocalcin; BMI, body mass index; OGTT, oral glucose tolerance test; ALP, alkaline phosphatase; HDL-C, high density lipoprotein total cholesterol; TC, total cholesterol; TG, triglyceride; HCG, human chorionic gonadotropin; E₂, estrogen; TRACP-5b, tartrate-resistant acid phosphatase 5b; LEP, leptin; ADP, adiponectin; CRP, C-reactive protein.

Adjusted for the BMI and age.

**Figures**
Figure 1

Osteocalcin exerts an autocrine loop in trophoblast. a: OCN umbilical vein serum levels were significantly higher than those in umbilical arterial serum and maternal serum. b: Immunohistochemical staining of placental tissue for OCN and GPRC6A. Seven days after JAR trophoblast cells osteogenic differentiation. c: The expression of OCN, Demp1, CollA1 was significantly elevated. d: Alizarin Red S stained. E: Transmission electron microscopic images. OCN improved JAR trophoblast cells (e) proliferation, (f) HCG secretion, (g) ADP, aromatase-related genes, genes encoding inflammatory factors synthesis. GPRC6A gene knockdown by shRNA in JAR trophoblast cells, decrease (h) proliferation, (i) HCG secretion, (j) aromatase-related genes and genes encoding inflammatory factors synthesis. The data are presented
as the mean ± SE of the values obtained in 3 independent experiments. * P < 0.05, ** P < 0.01, ***P < 0.001). OCN, osteocalcin; HCG: Human Chorionic Gonadotropin; ADP, adiponectin.

![Module-trait relationships](image)

**Figure 2**

Module-trait associations. Each row corresponds to a module eigengene, and the columns correspond to clinical indexes. Red indicates a positive correlation, and green indicates a negative correlation. Each cell contains the corresponding correlation and P-value.
Figure 3

Schematic diagram of OCN autocrine of trophoblast in GDM. Lower trophoblasts synthesis OCN contributes to placenta dysfunction in GDM. Lower OCN resulted in a decrease in HCG, IL-6, TNF-α, and ADP levels were reduced, but LEP increased.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- TableS1.docx
- TableS2.docx
- TableS3.docx
- TableS4.docx
- figureS1.tif
- figureS2.tif
- figureS3.tif
- figureS4.tif
- supplementalfigurelegend.docx